The Next Frontier for Biosimilars Intrusion

Posted by Will Gatziolis on Jul 25, 2019 8:00:00 AM

Eric Detwiler, Sandeep Sangwan and Christina Corridon co-wrote this blog post with Will Gatziolis.

As of mid-2019, the U.S. market has seen considerable competition from biosimilars in supportive oncology care. The next U.S. biosimilar frontier is therapeutic oncology care, where Genentech’s big trio—Rituxan, Herceptin and Avastin—will likely attempt to hold their ground against biosimilars. Reference product manufacturers and biosimilar manufacturers have been closely monitoring U.S. biosimilar uptake to understand how this market is likely to evolve, but diverse go-to-market and defense strategies may leave us with more questions than answers. As pricing pressure mounts in the U.S., so does pressure on biosimilar uptake, leaving reference product manufacturers and biosimilar manufacturers alike wondering what biosimilar uptake will look like in the therapeutic oncology space, and how much price erosion can be expected due to biosimilar competition.


>
Read More